3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Head & Neck
3
Gynecologic
3
Endocrine
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Neuroendocrine Tumors
208
Carcinoid Tumor
26
Neoplasms
22
Pancreatic Neoplasms
16
Gastro-enteropancreatic neuroendocrine tumor
14
Carcinoma, Neuroendocrine
11
Carcinoma
11
Adenoma, Islet Cell
11
Neoplasm Metastasis
10
Colorectal Neoplasms
9
Lung Neoplasms
8
Serotonin Syndrome
7
Prostatic Neoplasms
7
Adenocarcinoma
7
Pheochromocytoma
6
Gastrointestinal Neoplasms
6
Colonic Neoplasms
6
Breast Neoplasms
6
Thyroid Neoplasms
5
Stomach Neoplasms
5
Somatostatinoma
5
Neuroblastoma
5
Melanoma
5
Gastroenteropancreatic Neuroendocrine Tumors
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
5
Vipoma
4
Sarcoma
4
Rectal Neoplasms
4
Paraganglioma
4
Interventions
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Endocrine System Diseases
×
NET
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA